Endometrial cancer, also known as uterine body cancer, refers to cancer of the endometrium, the majority of which is adenocarcinoma. It is one of the three most common malignant tumors of the female reproductive tract. The high incidence age is 58-61 years old. There are two staging standards for endometrial cancer, one is clinical staging, and for surgical treatment, surgical-pathological staging is used. Clinical staging: Stage 0 refers to adenomatous hyperplasia or carcinoma in situ; stage I refers to carcinoma confined to the uterine body; stage II refers to carcinoma invading the cervix; stage III refers to carcinoma spreading to the pelvis outside the uterus but not beyond the true pelvis; stage IV refers to carcinoma beyond the true pelvis or invading the bladder or rectal mucosa or spreading outside the pelvis. Surgical-pathological staging: Stage Ia refers to cancer confined to the endometrium, stage Ib refers to invasion of myometrium ≤ 1/2, stage Ic refers to invasion of myometrium > 1/2, stage IIa refers to involvement of cervical mucosal glands, stage IIb refers to invasion of cervical mesenchyme, stage IIIa refers to cancer invading the plasma membrane and/or adnexa and/or positive abdominal cytology, stage IIIb refers to vaginal metastasis, stage IIIc refers to pelvic and/or para-aortic lymph node metastasis, stage IVa refers to cancer invading bladder and/or rectal mucosa, and stage IVb refers to distant metastasis, including intra-abdominal and/or inguinal lymph node metastasis. Currently, surgical-pathological staging is now used for endometrial cancer, and clinical staging is still used for a few patients when radiotherapy is chosen first, but it should be indicated.